Clinical Trial Update: Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating venetoclax with romidepsin in recurrent or refractory mature T-cell lymphoma and related NK/T-cell non-Hodgkin lymphomas has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma

Drugs mentioned

• Romidepsin (romidepsin)
• Venetoclax (venetoclax)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-22